13th Mar 2009 10:00
Tepnel Life Sciences plc ('Tepnel' or 'the Company')
Exercise of Options
Manchester, UK, 13 March 2009: Tepnel Life Sciences PLC (AIM: TED), the international Molecular Diagnostics and Research Products & Services group, today announces that the Board of Directors approved the issue of 535,722 new Ordinary Shares of 1 pence each in connection with the exercise of options as detailed below:
|
Number |
Exercise Price (pence) |
|
525,722 |
6.125 |
|
10,000 |
22 |
Application has been made by the Company for the 535,722 new Ordinary Shares to be admitted to the AIM market. It is expected that Admission will become effective and that dealings on AIM will commence on or around 19 March 2009.
Following admission to AIM of the new Ordinary Shares, the total number of Ordinary Shares in issue will be 249,716,692.
-End-
For further information:
Tepnel Life Sciences plc
Ben Matzilevich, CEO
Michael Slater, Group Finance Director
Carol Smith, Group Marketing Communications Manager
Tel: 0161 946 2200
Capital MS&L
Mary Clark or Catie Corcoran
Tel: +44 20 7307 5330
Seymour Pierce Limited
Mark Percy
Tom Sheldon
Christopher Wren
Tel: +44 20 7107 8000
About Tepnel Life Sciences plc
Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences products and services Group with two divisions, Molecular Diagnostics and Research Products & Services. The Company has laboratories, manufacturing and operations in the USA, UK and France with over 200 employees. Tepnel provides test kits, reagents and services to two highly synergistic markets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunities within these multi-billion pound markets. Tepnel focuses on these niche operations with internally developed products, patents, expertise and know-how as well as strategic acquisitions, to develop a leadership position within these defined market segments. For more information please visit www.tepnel.com.
Related Shares:
TED.L